연구성과로 돌아가기

2023 연구자 정보 (61 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Kim, Mimi
(Kim, M)
제1저자 Hanyang Univ, Coll Med, Seoul, South Korea G-5001-2015
Kim, Chang

[JCR상위 1.7] The role of M2BPGi in screening for advanced hepatic fibrosis in diabetic patients
[JCR상위 1.7] The role of M2BPGi for screening of advanced hepatic fibrosis in elderly patients
[JCR상위 1.7] Fibrosis-4 and M2BPGi combination screening algorithm for screening advanced hepatic fibrosis in diabetes is cost-effective
SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY noshin@hanyang.ac.kr;
Kim, Min Kyoon
(Kim, MK)


[JCR상위 1.7] Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial) SCIE 1.7 ONCOLOGY
Kim, Soo-Yeon
(Kim, SY)
J-5441-2012
Kim, Jee

[JCR상위 1.7] Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial) SCIE 1.7 ONCOLOGY
Kim, Tae-Yong
(Kim, TY)
Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea C-1272-2009
Kim, Tae

[JCR상위 1.7] ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer
[JCR상위 34.6] Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
[JCR상위 34.6] Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach (vol 23, pg 3, 2023)
SCIE 1.7 ONCOLOGY
GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY
hyesukhan@chungbuk.ac.kr;nam20131114@gmail.com;seongho.kong@snu.ac.kr;
Ko, Bor-Sheng
(Ko, BS)
Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study SCIE 1.7 ONCOLOGY dmiklos@stanford.edu;
Koh, Jiwon
(Koh, J)


[JCR상위 1.7] Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial) SCIE 1.7 ONCOLOGY
Komura, Takuya
(Komura, T)
Kanazawa Med Ctr, Kanazawa, Ishikawa, Japan

[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY robert.c.elston@gsk.com;
Kook, Yoonwon
(Kook, Y)


[JCR상위 1.7] Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25) SCIE 1.7 ONCOLOGY
Koustenis, Andrew
(Koustenis, A)


[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer SCIE 1.7 ONCOLOGY
Kudo, Masatoshi
(Kudo, M)
Kindai Univ, Osaka, Japan AAA-9744-2019
Kudo, Masatoshi

[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
[JCR상위 0.2] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial
SCIE 0.2 ONCOLOGY
MEDICINE, GENERAL & INTERNAL
pierce.chow@duke-nus.edu.sg;
Kuswidiyanto, Lukas Wiku
(Kuswidiyanto, LW)
제1저자 Kangwon Natl Univ, Coll Agr & Life Sci, Interdisciplinary Program Smart Agr, Chunchon, South Korea

[JCR상위 1.7] Airborne hyperspectral imaging for early diagnosis of kimchi cabbage downy mildew using 3D-ResNet and leaf segmentation SCIE 1.7 AGRICULTURE, MULTIDISCIPLINARY;COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS hanxiongzhe@kangwon.ac.kr;
Kuwahara, Yusuke
(Kuwahara, Y)


[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 SCIE 1.7 ONCOLOGY
Kwon, Hyuk-Jun
(Kwon, HJ)
교신저자 DGIST, Dept Elect Engn & Comp Sci, Daegu 42988, South Korea
DGIST, Convergence Res Adv Ctr Olfact, Daegu 42988, South Korea

0000-0002-4767-7444
Kwon, Hyuk-Jun
[JCR상위 1.7] Schottky barrier modulation of bottom contact SnO2 thin-film transistors via chloride-based combustion synthesis SCIE 1.7 MATERIALS SCIENCE, MULTIDISCIPLINARY;METALLURGY & METALLURGICAL ENGINEERING hj.kwon@dgist.ac.kr;
Lau, George
(Lau, G)
제1저자 AAQ-2085-2021
Lau, George

[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) SCIE 1.7 ONCOLOGY
Lee, Han-Byoel
(Lee, HB)


[JCR상위 1.7] Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25)
[JCR상위 1.7] Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial)
SCIE 1.7 ONCOLOGY
페이지 이동: